Expertise in
23
conditions

Toshiaki Takahashi

Shizuoka, JP 
Expertise in
23
conditions
Shizuoka, JP 
OverviewLocationsClinical Research

Overview

Toshiaki Takahashi practices in Shizuoka, Japan. Mr. Takahashi is highly rated in 23 conditions, according to our data. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), EGFR Positive Lung Cancer, Endoscopy, and Hemorrhoidectomy.

His clinical research consists of co-authoring 309 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years.

Gender
Male

Locations

Shizuoka, Japan
Other Locations
Shimonagakubo, 4118777, Japan
Okayama, Japan
Tokyo, Japan
Toranomon, Japan
Ichihara, 2900045, Japan
Kamogawa, Japan
Yokote, Japan
Akita, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Multicenter, Double Blind, Randomized, Controlled Study of M7824 With Concurrent Chemoradiation Followed by M7824 Versus Concurrent Chemoradiation Plus Placebo Followed by Durvalumab in Participants With Unresectable Stage III Non-small Cell Lung Cancer
A Multicenter, Double Blind, Randomized, Controlled Study of M7824 With Concurrent Chemoradiation Followed by M7824 Versus Concurrent Chemoradiation Plus Placebo Followed by Durvalumab in Participants With Unresectable Stage III Non-small Cell Lung Cancer
Enrollment Status: Terminated
Publish Date: January 16, 2024
Intervention Type: Drug, Radiation
Study Drugs: M7824, Durvalumab, Etoposide, Pemetrexed, Carboplatin, Paclitaxel, Cisplatin
Study Phase: Phase 2

309 Total Publications

Initial Patient Characteristics Associated With Ineligibility for Second-Line Therapy After Progression on First-Line Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer.
Initial Patient Characteristics Associated With Ineligibility for Second-Line Therapy After Progression on First-Line Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer.
Journal: Thoracic cancer
Published: September 23, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Takahashi's expertise for a condition
ConditionClose
View All 17 Advanced Conditions
View All 35 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile